Audience: General Public, Healthcare Professionals
Department: Health Canada
Summary
Issue
Health Canada has updated the product information for the Pfizer-BioNTech COVID-19 vaccine to describe very rare reports of Bell’s Palsy (typically temporary weakness or paralysis on one side of the face) following vaccination.
Product
Pfizer-BioNTech COVID-19 vaccine
What to do
Seek medical attention if you experience any combination of the following symptoms after vaccination: uncoordinated movement of the muscles that control facial expression; loss of feeling in the face; headache; tearing from the eye; drooling; lost sense of taste on the front two-thirds of the tongue; hypersensitivity to sound in one ear; or inability to close an eye on one side of the face.
Get told about the next health product recall.
We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.
Health Canada has updated the product information for the Pfizer-BioNTech COVID-19 vaccine to describe very rare reports of Bell’s Palsy (typically temporary weakness or paralysis on one side of the face) following vaccination. Cases have been reported in a small number of people in Canada and internationally.
The Moderna COVID-19 vaccine label already contains safety information about reported cases of Bell’s Palsy following vaccination and the Department is continuing to assess this issue for all authorized COVID-19 vaccines in Canada.
Bell's Palsy is an episode of facial muscle weakness or paralysis. The condition is typically temporary. Symptoms appear suddenly and generally start to improve after a few weeks. The exact cause is unknown. It's believed to be the result of swelling and inflammation of the nerve that controls muscles on one side of your face.
Health Canada reassures Canadians that COVID-19 vaccines continue to be safe and effective at protecting them against COVID-19. The benefits of COVID-19 vaccines continue to outweigh their potential risks, as scientific evidence shows that they reduce deaths and hospitalizations due to COVID-19.
Health Canada will continue to work with manufacturers, as well as domestic and international partners, to gain a better understanding of the potential relationship between COVID-19 vaccines and adverse events. The Department will take further action if necessary.